Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where M. Karen Newell is active.

Publication


Featured researches published by M. Karen Newell.


Cell | 2007

The CD95 Receptor: Apoptosis Revisited

Marcus E. Peter; Ralph C. Budd; Julie Desbarats; Stephen M. Hedrick; Anne-Odile Hueber; M. Karen Newell; Laurie B. Owen; Richard M. Pope; Juerg Tschopp; Harald Wajant; David Wallach; Robert H. Wiltrout; Martin Zörnig; David H. Lynch

CD95 is the quintessential death receptor and, when it is bound by ligand, cells undergo apoptosis. Recent evidence suggests, however, that CD95 mediates not only apoptosis but also diverse nonapoptotic functions depending on the tissue and the conditions.


The FASEB Journal | 2002

Characterization of a novel metabolic strategy used by drug-resistant tumor cells

Mary-Ellen Harper; Andreas Antoniou; Elizabeth Villalobos-Menuey; Alicia Russo; Richard J. Trauger; Minda Vendemelio; Amanda George; Richard M. Bartholomew; Dennis J. Carlo; Azhar Shaikh; Jami Kupperman; Evan W. Newell; Ivan A. Bespalov; Susan S. Wallace; Ye Liu; Jeffrey R. Rogers; Gregory L. Gibbs; Jack L. Leahy; R. E. Camley; Robert J. Melamede; M. Karen Newell

Acquired or inherent drug resistance is the major problem in achieving successful cancer treatment. However, the mechanism(s) of pleiotropic drug resistance remains obscure. We have identified and characterized a cellular metabolic strategy that differentiates drug‐resistant cells from drug‐sensitive cells. This strategy may serve to protect drug‐resistant cells from damage caused by chemotherapeutic agents and radiation. We show that drug‐resistant cells have low mitochondrial membrane potential, use nonglucose carbon sources (fatty acids) for mitochondrial oxygen consumption when glucose becomes limited, and are protected from exogenous stress such as radiation. In addition, drug‐resistant cells express high levels of mitochondrial uncoupling protein 2 (UCP2). The discovery of this metabolic strategy potentially facilitates the design of novel therapeutic approaches to drug resistance.—Harper, M.‐E., Antoniou, A., Villalobos‐Menuey, E., Russo, A., Trauger, R., Vendemelio, George, A. M., Bartholomew, R., Carlo, D., Shaikh, A., Kupperman, J., Newell, E. W., Bespalov, I. A., Wallace, S. S., Liu, Y., Rogers, J. R., Gibbs, G. L., Leahy, J. L., Camley, R. E., Melamede, R., Newell, M. K. Characterization of a novel metabolic strategy used by drug‐resistant tumor cells. FASEB J. 16, 1550–1557 (2002)


Journal of Immunology | 2000

Vγ1 + T Cells Suppress and Vγ4 + T Cells Promote Susceptibility to Coxsackievirus B3-Induced Myocarditis in Mice

Sally A. Huber; Danielle Graveline; M. Karen Newell; Willi K. Born; Rebecca L. O’Brien

Coxsackievirus B3 infections of C57BL/6 mice, which express the MHC class II IA but not IE Ag, results in virus replication in the heart but minimal myocarditis. In contrast, Bl.Tg.Eα mice, which are C57BL/6 mice transgenically induced to express IE Ag, develop significant myocarditis upon Coxsackievirus B3 infection. Despite this difference in inflammatory damage, cardiac virus titers are similar between C57BL/6 and Bl.Tg.Eα mice. Removing γδ T cells from either strain by genetic manipulation (γδ knockout(ko)) changes the disease phenotype. C57BL/6 γδ ko mice show increased myocarditis. In contrast, Bl.Tg.Eα γδ ko mice show decreased cardiac inflammation. Flow cytometry revealed a difference in the γδ cell subsets in the two strains, with Vγ1 dominating in C57BL/6 mice, and Vγ4 predominating Bl.Tg.Eα mice. This suggests that these two Vγ-defined subsets might have different functions. To test this possibility, we used mAb injection to deplete each subset. Mice depleted of Vγ1 cells showed enhanced myocarditis, whereas those depleted of Vγ4 cells suppressed myocarditis. Adoptively transfusing enriched Vγ4+ cells to the C57BL/6 and Bl.Tg.Eα γδ ko strains confirmed that the Vγ4 subset promoted myocarditis. Th subset analysis suggests that Vγ1+ cells biased the CD4+ T cells to a dominant Th2 cell response, whereas Vγ4+ cells biased CD4+ T cells toward a dominant Th1 cell response.


Journal of Immune Based Therapies and Vaccines | 2006

Cellular metabolism as a basis for immune privilege

M. Karen Newell; Elizabeth Villalobos-Menuey; Susan C Schweitzer; Mary-Ellen Harper; R. E. Camley

We hypothesize that the energy strategy of a cell is a key factor for determining how, or if, the immune system interacts with that cell. Cells have a limited number of metabolic states, in part, depending on the type of fuels the cell consumes. Cellular fuels include glucose (carbohydrates), lipids (fats), and proteins. We propose that the cells ability to switch to, and efficiently use, fat for fuel confers immune privilege. Additionally, because uncoupling proteins are involved in the fat burning process and reportedly in protection from free radicals, we hypothesize that uncoupling proteins play an important role in immune privilege. Thus, changes in metabolism (caused by oxidative stresses, fuel availability, age, hormones, radiation, or drugs) will dictate and initiate changes in immune recognition and in the nature of the immune response. This has profound implications for controlling the symptoms of autoimmune diseases, for preventing graft rejection, and for targeting tumor cells for destruction.


Journal of Immune Based Therapies and Vaccines | 2004

The effects of chemotherapeutics on cellular metabolism and consequent immune recognition.

M. Karen Newell; Robert Melamede; Elizabeth Villalobos-Menuey; Douglas Swartzendruber; Richard J. Trauger; R. E. Camley; William Crisp

A widely held view is that oncolytic agents induce death of tumor cells directly. In this report we review and discuss the apoptosis-inducing effects of chemotherapeutics, the effects of chemotherapeutics on metabolic function, and the consequent effects of metabolic function on immune recognition. Finally, we propose that effective chemotherapeutic and/or apoptosis-inducing agents, at concentrations that can be achieved physiologically, do not kill tumor cells directly. Rather, we suggest that effective oncolytic agents sensitize immunologically altered tumor cells to immune recognition and immune-directed cell death.


Shock | 2013

Inhibition of Fas-Fas ligand interaction attenuates microvascular hyperpermeability following hemorrhagic shock.

Devendra A. Sawant; Binu Tharakan; Richard Tobin; Hayden W. Stagg; Felicia A. Hunter; M. Karen Newell; W. Roy Smythe; Ed W. Childs

ABSTRACT Hemorrhagic shock (HS)–induced microvascular hyperpermeability poses a serious challenge in the management of trauma patients. Microvascular hyperpermeability occurs mainly because of the disruption of endothelial cell adherens junctions, where the “intrinsic” apoptotic signaling plays a regulatory role. The purpose of this study was to understand the role of the “extrinsic” apoptotic signaling molecules, particularly Fas–Fas ligand interaction in microvascular endothelial barrier integrity. Rat lung microvascular endothelial cells (RLMECs) were exposed to HS serum in the presence or absence of the Fas ligand inhibitor, FasFc. The effect of HS serum on Fas receptor and Fas ligand expression on RLMECs was determined by flow cytometry. Endothelial cell permeability was determined by monolayer permeability assay and the barrier integrity by &bgr;-catenin immunofluorescence. Mitochondrial reactive oxygen species formation was determined using dihydrorhodamine 123 probe by fluorescent microscopy. Mitochondrial transmembrane potential was studied by fluorescent microscopy as well as flow cytometry. Caspase 3 enzyme activity was assayed fluorometrically. Rat lung microvascular endothelial cells exposed to HS serum showed increase in Fas receptor and Fas ligand expression levels. FasFc treatment showed protection against HS serum-induced disruption of the adherens junctions and monolayer hyperpermeability (P < 0.05) in the endothelial cells. Pretreatment with FasFc also decreased HS serum-induced increase in mitochondrial reactive oxygen species formation, restored HS serum-induced drop in mitochondrial transmembrane potential, and reduced HS serum-induced caspase 3 activity in RLMECs. These findings open new avenues for drug development to manage HS-induced microvascular hyperpermeability by targeting the Fas–Fas ligand–mediated pathway.


International Journal of Bioinformatics Research and Applications | 2006

A rich analytical environment for flow cytometry experimental results

Janet Siebert; Krzysztof J. Cios; M. Karen Newell

Existing analysis tools for flow cytometry data offer specialised but limited functionality. This work presents advantages of combining the cytometers data with sample-specific information. Data is loaded into a relational database, where the analyst can query based on sample characteristics such as species, gender, diet type or sample stain type.


Nature Cell Biology | 2003

Fas engagement induces neurite growth through ERK activation and p35 upregulation

Julie Desbarats; Raymond B. Birge; Manuelle Mimouni-Rongy; David E. Weinstein; Jean-Sébastien Palerme; M. Karen Newell


Archive | 2010

B3-Induced Myocarditis in Mice Susceptibility to Coxsackievirus V{gamma}4+ T Cells Promote V{gamma}1+ T Cells Suppress and

Willi K. Born; Rebecca L. O'Brien; Sally A. Huber; Danielle Graveline; M. Karen Newell


Archive | 2009

Uncoupling Cellular Respiration: A Link to Cancer Cell Metabolism and Immune Privilege

M. Karen Newell; Elizabeth Villalobos-Menuey; Marilyn Burnett; Robert E. Camley

Collaboration


Dive into the M. Karen Newell's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

R. E. Camley

University of Colorado Colorado Springs

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David E. Weinstein

Albert Einstein College of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge